Who
James Paul Scopa
Director
Company insider
Files Form 4 as: Director, Aligos Therapeutics; Director, Adverum Biotechnologies; Director, DICE Therapeutics; Director, Conatus Pharmaceuticals; Director, TriVascular Technologies; 10% owner, Chiasma; 10% owner, Pacira BioSciences; Director and 10% owner, Peplin.
In numbers
- Trades disclosed
- 120
- Buys
- 19
- Sells
- 2
- Bought
- $6.3M
- Sold
- $400K
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 13 Jan 2009
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,666 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,500 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —10,520 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code D | —10,450 | filing |
| 9 Dec 2025filed 10 Dec 2025 | Adverum Biotechnologies | SEC FORM 4 Code U | —10,333 | filing |
| 25 Jun 2025filed 26 Jun 2025 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code A | —10,450 at $0.00 | filing |
| 27 Jun 2024filed 28 Jun 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | Adverum Biotechnologiesoption or derivative | SEC FORM 4 Code A | —10,520 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,823 at $0.00 | filing |
| 27 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | Adverum Biotechnologies | SEC FORM 4 Bought | $135K100,000 at $1.35 | filing |
| 25 Oct 2023filed 27 Oct 2023 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $12K91,541 at $0.13 | filing |
| 25 Oct 2023filed 27 Oct 2023 | ALGS Aligos TherapeuticsBiotechnology | SEC FORM 4 Code A | $139K183,083 at $0.76 | filing |
News
Pacira BioSciences (NASDAQ:PCRX) Upgraded at JPMorgan Chase & Co.PCRX · themarketsdaily.com · 11 Oct 2026Insider Selling: Pacira BioSciences (NASDAQ:PCRX) SVP Sells $217,920.00 in StockPCRX · themarketsdaily.com · 10 Oct 2026Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ)PCRX · seekingalpha.com · 8 Oct 2026
0 headlines in the last 90 days name James Paul Scopa; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.